anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: To observe the clinical efficacy of acupoint massage at Shenque (CV 8) for chronic fatigue syndrome (CFS).
METHODS: A total of 71 patients with CFS were randomized into an observation group (36 cases, 2 cases were eliminated, 3 cases dropped out) and a control group (35 cases). Using a specially made massage instrument, acupoint massage was adopted at the the five points of Shenque (CV 8), i.e. the center and the upper, lower, left, and right parts of the inner wall. The manipulation was given 10 min a time, once every 2 days, 3 times a week for 4 weeks continuously. No intervention was delivered in the control group. Before and after treatment, the scores of fatigue scale-14 (FS-14) and Pittsburgh sleep quality index (PSQI) were observed, and the clinical efficacy was evaluated in the both groups.
RESULTS: After treatment, the physical fatigue and mental fatigue scores, as well as the total score of FS-14 were decreased compared with those before treatment in the observation group (P<0.001); the above scores in the observation group were lower than those in the control group (P<0.001). After treatment, excepted for the sleep time and hypnotic scores, the remaining item scores and the total score of PSQI were decreased compared with those before treatment in the observation group (P<0.05); the each item score and the total score of PSQI were lower than those in the control group (P<0.05). The total effective rate in the observation group was superior to that in the control group (P<0.01).
CONCLUSIONS: Acupoint massage at Shenque (CV 8) can effectively improve the fatigue state and sleep quality in patients with chronic fatigue syndrome.
Congenital cataract patients have a wide range of presentations of lens opacities with different impact on visual function. Polar cataracts are opacities of the subcapsular cortex in the polar regions of the lens. To our knowledge, anterior polar cataracts are usually visually insignificant, however, even a small posterior lens opacity can impair vision because of their close proximity to the macula. Visual impairment could be caused by an opacity that blocks the visual axis, refractive error, posterior lesion-induced optical distortion, or amblyopia. Therefore, surgery is often recommended when visual function is significantly affected. The primary indication for surgical intervention in cataract is poor visual acuity. However, the previous studies have shown that preoperative visual acuity is a poor predictor of improvement in the subjectively experienced quality of vision after cataract surgery. Considering the increased risk for capsule rupture during surgery and the sacrifice of accommodation after cataract surgery in eyes with posterior lens opacities, the decision of surgical intervention must be carefully weighed.

In this trial, the investigators aimed to evaluate the changes of visual function, including visual acuity, modulation transfer function, ocular aberrations in the participants with posterior lens opacities. Moreover, various factors which might be associated with postoperative visual acuity were explored. The participants enrolled in this study will be followed for at least 6 months and will have study visits at 1 day, 1 week, 1 month, 3 month, 6 month postoperatively.
PROBLEM TO BE SOLVED: To obtain a new response regulator consisting of an isolated polypeptide containing an amino acid sequence having an identity to a specific amino acid sequence at various levels, for screening of antibacterial compounds. treatment and diagnosis of bacterial infection, and so on. SOLUTION: This response regulator consists of an isolated polypeptide containing an amino acid sequence having an identity, throughout formula I or II. of at least, 70%, 80%, 90%, or 95% to the amino acid sequence shown by formula I or II. an amino acid sequence shown by formula I or II, or an isolated polypeptide containing these amino acid sequences, and is useful for screening of antibacterial compounds, treatment and diagnosis of infection by Streptococcus pneumoniae. and so on. This isolated polypeptide is obtained by introducing a polynucleotide obtained by probing a chromosomal DNA library of S. pneumoniae with a labelled oligonucleotide from the partial sequence into an expression system, and expressing in a host cell.
The next step in determining the role of remote patient monitoring in the management of patients with heart failure is to better understand which patients are most likely to benefit from a more intensive outpatient management or simply conservative management. The subject population is patients with mild HFrEF or HFpEF who are prone to readmission. This patient population does not have implanted devices to supply objective data to evaluate patient's volume status and therefore can be challenging to manage on an outpatient basis. By providing regular data on weight, blood pressure, pulse oximetry, electrocardiogram and heart/lung sounds that is reviewed on a monthly basis, this may allow a clinician greater insight into their patient's clinical status and allow for a more accurate and timely intervention to prevent clinical deterioration. Furthermore, this should enhance patient engagement with their own health as well as with their healthcare provider. This study would significantly add to the current knowledge of management of heart failure in an ambulatory patient population without implanted devices.
The invention discloses a moisturizing composition, application thereof and a moisturizing essence, and relates to the field of cosmetics. The moisturizing composition comprises the following components in parts by weight: 1-9 parts of glycerol; 1-9 parts of butanediol; betaine 0.5-5 parts; polyethylene glycol-8 0-2 parts. The glycerin and the butanediol have strong hygroscopicity, can form a film on the surface of the skin, lock moisture in the skin on the stratum corneum, and can absorb water molecules in the air. Unlike polyol moisturizers, betaine releases water molecules easily when physical conditions change, and allows water molecules to be utilized by living cells, and has antiallergic and skin irritation reducing effects. Polyethylene glycol-8 acts as a lubricant and has the excellent properties of non-volatility, physiological inertia, mildness, lubricity and skin moistening and softening. The traditional moisturizing agent is selected for matching, has moderate viscosity, smooth touch, low cost and high moisturizing effect.
The use of RENFLEXIS at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure. A randomized, double-blind, placebo-controlled study evaluated the use of infliximab (5 mg/kg or 10 mg/kg at Weeks 0, 2, and 6) in patients with moderate or severe heart failure [New York Heart Association (NYHA) Functional Class III/IV]. Compared to patients who received placebo, there was a higher rate of mortality and a higher risk of hospitalization at Week 28 due to heart failure in patients who received the 10 mg/kg infliximab dose, and higher rates of cardiovascular adverse events in patients who received infliximab doses of 5 mg/kg and 10 mg/kg.

There have been post-marketing reports of new onset and worsening heart failure, with and without identifiable precipitating factors (e.g., pre-existing cardiovascular disease), in patients treated with infliximab products. Some of these patients have been under 50 years of age.

If a decision is made to administer RENFLEXIS (≤ 5 mg/kg) to patients with moderate or severe heart failure or to administer RENFLEXIS (any approved dose) to patients with mild heart failure, they should be closely monitored during therapy, and RENFLEXIS should be discontinued if new or worsening symptoms of heart failure appear [see Contraindications (4) and Adverse Reactions (6.1)].
LY2523355 administered intravenously on Days 1 and 8, starting dose is 8 mg/m\^2 for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
The objective of this double-blind prospective randomized clinical trial is to compare the effects of PRP to HA in patients with mild to moderate OA using biologic and clinical correlates of outcomes associated with the treatment of OA. The investigators will test the null hypothesis that there are no differences in clinical outcomes as measured by validated clinical scoring systems for OA, nor is there any difference in intra-articular biology between groups of patients treated with HA and those treated with PRP over time.

This study was a prospective, randomized, double blind, comparative clinical trial with an allocation ratio of 1:1 that underwent IRB approval at the principal institution. Between 2011 and 2014 patients will be screened for participation. All comers with a diagnosis of osteoarthritis of the knee between 18 and 80 years of age will be screened.

Treatment and Evaluation Patients who meet inclusion criteria will be randomized via an electronic randomization process into two groups: one receiving intra-articular PRP and the other, intra-articular HA. Non-clinical staff will perform randomization, clinical staff performed the injections, and results and analyses will be performed by the primary research team. Patients and the primary research team performing analysis will be blinded to assignments. All patients will undergo a 10 ml blood draw for PRP preparation and a 3 ml peripheral blood draw for a complete blood count with leukocyte differential. This will be performed on patients who received HA to maintain patient blinding and to characterize the peripheral white blood cells (WBC) and platelet counts. A complete blood count (CBC) will be completed on PRP prior to injection to evaluate the fold increase in platelet concentration and to confirm rarity of red white blood cells. A synovial fluid aspirate of approximately 2cc will be performed under ultrasound guidance just prior to each PRP or HA injection for ELISA analysis of basal and post-treatment intra-articular environment. After treatment, patients will be instructed to limit the use of the leg for at least 24 hours and use cold therapy/icing for discomfort. During this treatment period rest or mild exertion activities (such as exercise bike, aquatic therapy) are recommended, followed by gradual return to sports or recreational activities as tolerated.
Teachers in the intervention group will receive a half day workshop from a member of the research team. These teachers will then provide a four week training program to Grade 6/7 students, who will then deliver a 10-week fundamental movement skill (FMS) training program to Grade 3/4 students.
PROBLEM TO BE SOLVED: To obtain a polymerization initiator requiring a short time for hardening, and capable of providing good adhesive properties to the obtained hardened product by including an organic boron compound, an organic peroxide and a reducing agent. SOLUTION: This polymerization initiator comprises (A) 100 pts.wt. organic boron compound, preferably the one selected from a trialkylboron, an alkoxyalkylboron, a dialkylborane, and a partially oxidized trialkylboron (e.g. tributylboron or a partially oxidized tributylboron), (B) 0.1-50 pts.wt. organic peroxide, e.g. benzoyl peroxide, (C) 0.1-30 pts.wt. reducing agent, preferably an amine compound (e.g. N,N-dimethylaniline). The components B and C are preferably used in a weight ratio of (50:1)-(1:1) in the polymerization initiator. The polymerization initiator is useful as the one in a dental material using an acrylic monomer.
TRAF7-related disorders represent some of the rarest inherited disorders, exhibiting clinical features that overlap with cardiac, facial, and digital anomalies with developmental delay (CAFDADD) syndrome, as well as blepharophimosis-mental retardation syndrome (BMRS). A 36-year-old male, presenting with total blindness, blepharophimosis, and intellectual disability, was admitted for the assessment of resting dyspnea several months previously. He had a history of being diagnosed with obstructive sleep apnea (OSA). Transesophageal and transthoracic echocardiography unveiled right ventricular dilatation without significant pulmonary hypertension, bicuspid aortic valve with aortic root aneurysm, and aortic regurgitation in the proband. Sanger sequencing identified a de novo TRAF7 variant (c.1964G>A; p.Arg655Gln). Subsequently, aortic root replacement using the Bentall procedure was performed. However, despite the surgery, he continued to experience dyspnea. Upon re-evaluating OSA with polysomnography, it was discovered that continuous positive airway pressure support alleviated his symptoms. The underlying cause of his symptoms was attributed to OSA, likely exacerbated by the vertebral anomaly and short neck associated with CAFDADD syndrome. Clinicians should be attentive to the symptoms associated with OSA as it is a potentially serious medical condition in patients with TRAF7 variants.
After obtaining written consent from the patients who agreed to participate in the study, the patients included in the control group were asked to continue their rheumatologist follow-up and their normal lives (hospital routine, daily life). Patients in this group will fill out the "Patient Description Form, Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire, McGill Pain Scale Short Form, Stanford Health Evaluation Questionnaire" at the first interview. After 3 months, data collection tools other than the "Patient Identification Form" will be applied to the patients and the training guide to be prepared for rheumatoid arthritis patients will be given.
Insomnia and suicidal ideation (SI) are common in schizophrenia, including in individuals at clinical high-risk for psychosis (CHR-P). Previous studies have found associations between sleep disturbance, SI, and psychopathology in schizophrenia. We explored these associations in a CHR-P cohort. We leveraged data from CHR-P individuals in the North American Prodrome Longitudinal Studies (NAPLS-3) (n = 688) cohort. We investigated relationships between sleep disturbance (Scale of Prodromal Symptoms [SOPS]; Calgary Depression Scale for Schizophrenia [CDSS], and the Pittsburgh Sleep Quality Index [PSQI]), suicidal ideation (CDSS), and psychosis-risk symptoms. The prevalence of terminal insomnia, sleep disturbance, and SI in NAPLS3 was 25 %, 69 %, and 29 %, respectively. After controlling for potential confounders, multiple indices of sleep disturbance (SOPS, PSQI: OR = 1.05-1.40) were significant indicators of concurrent SI. Terminal insomnia was not associated with conversion to psychosis. Multiple indices of sleep problems were associated with higher total and subscale psychosis-risk symptom scores (β = 0.09-0.39). Sleep problems are prevalent and associated with SI and more severe psychosis-risk symptoms in CHR-P individuals. These findings underscore the importance of designing longitudinal intervention studies to investigate whether the treatment of sleep disturbances may reduce suicidality and symptoms in this population.
<P>PROBLEM TO BE SOLVED: To provide a moisturizer having a high skin-moisturizing ability and a cosmetic preparation.  <P>SOLUTION: The moisturizer contains an extract from a plant belonging to Saussurea spp., especially an extract from at least one plant chosen from the group consisting of Saussurea involucrate (Kar. et Kir.) Sch. Blp., Saussurea medusa Maxim. and Saussurea laniceps Hand. -Mazz. and glycerol as active ingredients. The cosmetic preparation preferably contains an extract from a plant belonging to Saussurea spp., especially an extract from at least one plant chosen from the group consisting of Saussurea involucrate (Kar. et Kir.) Sch. Blp., Saussurea medusa Maxim. and Saussurea laniceps Hand. -Mazz. and glycerol as active ingredients.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Adverse events occurring in approximately 10-30% of the subjects, in descending order of incidence, included oral dryness, ocular hyperemia, burning and stinging, headache, blurring, foreign body sensation, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, and ocular pruritus.

Events occurring in approximately 3-9% of the subjects, in descending order included corneal staining/erosion, photophobia, eyelid erythema, ocular ache/pain, ocular dryness, tearing, upper respiratory symptoms, eyelid edema, conjunctival edema, dizziness, blepharitis, ocular irritation, gastrointestinal symptoms, asthenia, conjunctival blanching, abnormal vision and muscular pain.

The following adverse reactions were reported in less than 3% of the patients: lid crusting, conjunctival hemorrhage, abnormal taste, insomnia, conjunctival discharge, depression, hypertension, anxiety, palpitations/arrhythmias, nasal dryness and syncope.

The following events have been identified during post-marketing use of brimonidine tartrate ophthalmic solution 0.2% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to brimonidine tartrate ophthalmic solution 0.2%, or a combination of these factors, include: bradycardia; hypotension; iritis; miosis; skin reactions (including erythema, eyelid pruritis, rash, and vasodilation); and tachycardia. Apnea, bradycardia, hypotension, hypothermia, hypotonia, and somnolence have been reported in infants receiving brimonidine tartrate ophthalmic solution 0.2%.
Methods are provided for validating theoretical improvements in the decision-support processes facilitating surveillance and monitoring of a patient's risk for developing a particular disease or condition and detecting the disease or condition. Patient information is received from a source and populated into an active risk assessment that monitors the patient's risk for developing Sepsis. At least a first and second set of actionable criteria for determining a patient's risk for developing sepsis are received. For each set of actionable criteria, it is determined that actionable criteria have been met. In some embodiments, software agents, operating in a multi-agent computing platform, perform each determination of whether actionable criteria are met. In some embodiments, in response to actionable criteria being met, a notification or alert is provided, and in some embodiments the results of the determinations of each set of actionable criteria are provided to facilitate validation of theoretical improvements.
A protocol of prophylactic 3% HTS as a volume expander with bolus (over 30 minutes) of 3% HTS at a dose of 250 ml every 6 hours for 7 days. This will be given through a central line as soon as possible and within 72 hours of onset of SAH symptoms.
PURPOSE: To assess the efficacy and safety of concurrent hypofractionated radiotherapy plus anti-PD-1 antibody and SOX chemotherapy in the treatment of metastatic pancreatic cancer (mPC) after failure of first-line chemotherapy.
METHODS: Patients with pathologically confirmed mPC who failed standard first-line chemotherapy were enrolled. The patients were treated with a regimen of hypofractionated radiotherapy, SOX chemotherapy, and immune checkpoint inhibitors at our institution. We collected the patients' clinical information and outcome measurements. The median progression-free survival (mPFS) was the primary endpoint of the study, followed by disease control rate (DCR), objective response rate (ORR), median overall survival (mOS) and safety. Exploratory analyses included biomarkers related to the benefits.
RESULTS: Between February 24, 2021, and August 30, 2023, twenty-five patients were enrolled in the study, and twenty-three patients who received at least one dose of the study agent had objective efficacy evaluation. The mPFS was 5.48 months, the mOS was 6.57 months, and the DCR and ORR were 69.5% and 30.4%, respectively. Among the seven patients who achieved a PR, the median duration of the response was 7.41 months. On-treatment decreased serum CA19-9 levels were associated with better overall survival. Besides, pretreatment inflammatory markers were associated with tumor response and survival.
CONCLUSIONS: Clinically meaningful antitumor activity and favorable safety profiles were demonstrated after treatment with these combination therapies in patients with refractory mPC. On-treatment decreased serum CA19-9 levels and pretreatment inflammatory markers platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), lactate dehydrogenase (LDH) might be biomarkers related to clinical benefits.
CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/showproj.html?proj=130211 , identifier: ChiCTR2100049799, date of registration: 2021-08-09.
The invention relates to a cordyceps sinensis mycelium solid fermentation extract and application thereof to the aspect of preparing an anti-fatigue product. The cordyceps sinensis mycelium solid fermentation extract is prepared from wild cordyceps sinensis (Berk.) Sacc. fruiting bodies through the steps of strain collection, preservation and rejuvenation, preparation of mother strain, primary liquid strain and secondary production strain, preparation of a solid fermentation substance, extraction of the solid fermentation extract and the like. Compared with the conventional liquid fermentation method, a method for preparing the cordyceps sinensis mycelium solid fermentation extract has the characteristics of simple process, environmental friendliness, no waste liquid discharge, low cost and the like, so that the method has wide practicability and operability. Experiments prove that mice loaded swimming time can be obviously prolonged by the cordyceps sinensis mycelium solid fermentation extract prepared with the method, so that the extract has a good anti-fatigue effect and can be used for preparing the anti-fatigue product.
A capnography device including a suitable sensor to measure carbon dioxide concentration for a target patient/user is provided. Such a device utilizes at least one microprocessor (MCU) to govern overall activation and communication between the capnograph and ultimately a data center. Such a component is provided with at least one RFID tag in order to charge device and transfer data via inductive coupling and to use as device ID for data routing purposes. The MCU may thus provide pre-programmed information to determine altert levels for a target patient/user, with the utilization of a data recordation device to capture all sensor results for such a target patient/user, too. If an alert occurs, the MCU transfers all subsequent information from the sensors to the data center. Thus, the inventive device and system provides a real-time, reliable, wireless surveillance and notification platform that has long been lacking.